2025 Q3 -tulosraportti
36 päivää sitten23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11. | |
| 2025 Q2 -tulosraportti | 15.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 20.3. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·18.12. · MuokattuCommercial breakthrough Two years after the approval of ProNephro AKI™ (NGAL), it is now possible to purchase the test through Roche Diagnostics. Finally, the test will be included in Roche's catalogs and marketing. For the first two years, sales have been limited to "research use only" From BioPorto's website today (US): "Commercial Availability ProNephro AKI™ (NGAL) – the first FDA-cleared test for AKI risk assessment in ICU patients ≥3 months to <22 years – is now available to order in the US. Integrating a damage biomarker like NGAL into patient assessment can help identify developing and persisting AKI in the 48-72 hours following ICU admission." "Make complex and potentially life-saving care decisions earlier and more confidently." "The First FDA-Cleared Test for Pediatric AKI ProNephro AKI™ (NGAL) for risk assessment – available through Roche Diagnostics." https://bioporto.us/pronephro-aki/
·1 päivä sittenQuite a flop this year, hope the stock gets momentum again.
·1 päivä sittenKeep an eye on the company's development. The price will eventually follow the upward or downward trend.
·15.12.As I wrote, it was expected that CB would field its own team. NHN had two titles, EVP (Executive Vice President) and CFO, which is quite a mess, because the boundaries become fluid. As we can read, there will be a change in the organizational structure. I am pretty sure that a change will be that NHN could not keep both his titles, which he was not happy with, and therefore he has found another job, outside BP. Today's equity news 12/12-2025 By Philip Coombes Equity Research Analyst 12.12.2025, 08.46 Bioporto announced yesterday after market close that Niels Høy Nielsen has chosen to resign from his position as CFO in BioPorto to take up a position as CFO in another company. Niels Høy Nielsen continues in his current role until March 2026, where the company in the meantime will assess the future organizational structure.·15.12. · MuokattuWhat? EVP indicates that the CFO has a place in management and is completely normal for a Chief Financial Officer. What kind of lame excuse is that? Do you remember you previously praised the CFO and his focus on sales and expansion? Once again you create a new narrative, which is adapted to the present, while you forget all your previous stories.·16.12.One thing is, it's fine that he gives his input, but otherwise, it's not a CFO's job to be the main commercial driving force. Another thing, it's fine that they internally at BP enjoy writing new smartly formulated visions or enjoy changing the team lineup. But that's just not what's needed. They don't sell a damn thing. So what's needed at BP are more, better, and more targeted commercial initiatives externally, out of the house...to where the customers are.- ·14.12.Perhaps Henrik Rom will apply for the position as CFO at BP. He has left Kamstrup, and during his time there, he helped to more than triple the revenue :-)·15.12.Comparison of Kamstrup and Bioporto? The only similarity must be that they both have a Danish CVR-nr. Kamstrup has an established business while BP is in the startup phase, in its 15th year, without having proven the basis for a profitable business.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
36 päivää sitten23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18.12. · MuokattuCommercial breakthrough Two years after the approval of ProNephro AKI™ (NGAL), it is now possible to purchase the test through Roche Diagnostics. Finally, the test will be included in Roche's catalogs and marketing. For the first two years, sales have been limited to "research use only" From BioPorto's website today (US): "Commercial Availability ProNephro AKI™ (NGAL) – the first FDA-cleared test for AKI risk assessment in ICU patients ≥3 months to <22 years – is now available to order in the US. Integrating a damage biomarker like NGAL into patient assessment can help identify developing and persisting AKI in the 48-72 hours following ICU admission." "Make complex and potentially life-saving care decisions earlier and more confidently." "The First FDA-Cleared Test for Pediatric AKI ProNephro AKI™ (NGAL) for risk assessment – available through Roche Diagnostics." https://bioporto.us/pronephro-aki/·1 päivä sittenQuite a flop this year, hope the stock gets momentum again.·1 päivä sittenKeep an eye on the company's development. The price will eventually follow the upward or downward trend.
- ·15.12.As I wrote, it was expected that CB would field its own team. NHN had two titles, EVP (Executive Vice President) and CFO, which is quite a mess, because the boundaries become fluid. As we can read, there will be a change in the organizational structure. I am pretty sure that a change will be that NHN could not keep both his titles, which he was not happy with, and therefore he has found another job, outside BP. Today's equity news 12/12-2025 By Philip Coombes Equity Research Analyst 12.12.2025, 08.46 Bioporto announced yesterday after market close that Niels Høy Nielsen has chosen to resign from his position as CFO in BioPorto to take up a position as CFO in another company. Niels Høy Nielsen continues in his current role until March 2026, where the company in the meantime will assess the future organizational structure.·15.12. · MuokattuWhat? EVP indicates that the CFO has a place in management and is completely normal for a Chief Financial Officer. What kind of lame excuse is that? Do you remember you previously praised the CFO and his focus on sales and expansion? Once again you create a new narrative, which is adapted to the present, while you forget all your previous stories.·16.12.One thing is, it's fine that he gives his input, but otherwise, it's not a CFO's job to be the main commercial driving force. Another thing, it's fine that they internally at BP enjoy writing new smartly formulated visions or enjoy changing the team lineup. But that's just not what's needed. They don't sell a damn thing. So what's needed at BP are more, better, and more targeted commercial initiatives externally, out of the house...to where the customers are.
- ·14.12.Perhaps Henrik Rom will apply for the position as CFO at BP. He has left Kamstrup, and during his time there, he helped to more than triple the revenue :-)·15.12.Comparison of Kamstrup and Bioporto? The only similarity must be that they both have a Danish CVR-nr. Kamstrup has an established business while BP is in the startup phase, in its 15th year, without having proven the basis for a profitable business.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11. | |
| 2025 Q2 -tulosraportti | 15.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 20.3. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
36 päivää sitten23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11. | |
| 2025 Q2 -tulosraportti | 15.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 20.3. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18.12. · MuokattuCommercial breakthrough Two years after the approval of ProNephro AKI™ (NGAL), it is now possible to purchase the test through Roche Diagnostics. Finally, the test will be included in Roche's catalogs and marketing. For the first two years, sales have been limited to "research use only" From BioPorto's website today (US): "Commercial Availability ProNephro AKI™ (NGAL) – the first FDA-cleared test for AKI risk assessment in ICU patients ≥3 months to <22 years – is now available to order in the US. Integrating a damage biomarker like NGAL into patient assessment can help identify developing and persisting AKI in the 48-72 hours following ICU admission." "Make complex and potentially life-saving care decisions earlier and more confidently." "The First FDA-Cleared Test for Pediatric AKI ProNephro AKI™ (NGAL) for risk assessment – available through Roche Diagnostics." https://bioporto.us/pronephro-aki/·1 päivä sittenQuite a flop this year, hope the stock gets momentum again.·1 päivä sittenKeep an eye on the company's development. The price will eventually follow the upward or downward trend.
- ·15.12.As I wrote, it was expected that CB would field its own team. NHN had two titles, EVP (Executive Vice President) and CFO, which is quite a mess, because the boundaries become fluid. As we can read, there will be a change in the organizational structure. I am pretty sure that a change will be that NHN could not keep both his titles, which he was not happy with, and therefore he has found another job, outside BP. Today's equity news 12/12-2025 By Philip Coombes Equity Research Analyst 12.12.2025, 08.46 Bioporto announced yesterday after market close that Niels Høy Nielsen has chosen to resign from his position as CFO in BioPorto to take up a position as CFO in another company. Niels Høy Nielsen continues in his current role until March 2026, where the company in the meantime will assess the future organizational structure.·15.12. · MuokattuWhat? EVP indicates that the CFO has a place in management and is completely normal for a Chief Financial Officer. What kind of lame excuse is that? Do you remember you previously praised the CFO and his focus on sales and expansion? Once again you create a new narrative, which is adapted to the present, while you forget all your previous stories.·16.12.One thing is, it's fine that he gives his input, but otherwise, it's not a CFO's job to be the main commercial driving force. Another thing, it's fine that they internally at BP enjoy writing new smartly formulated visions or enjoy changing the team lineup. But that's just not what's needed. They don't sell a damn thing. So what's needed at BP are more, better, and more targeted commercial initiatives externally, out of the house...to where the customers are.
- ·14.12.Perhaps Henrik Rom will apply for the position as CFO at BP. He has left Kamstrup, and during his time there, he helped to more than triple the revenue :-)·15.12.Comparison of Kamstrup and Bioporto? The only similarity must be that they both have a Danish CVR-nr. Kamstrup has an established business while BP is in the startup phase, in its 15th year, without having proven the basis for a profitable business.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt